Pharmalot Ed Silverman STAT Plus: Solicitor general recommends Supreme Court shouldn’t review an Amgen patent case
Pharmalot Ed Silverman STAT Plus: Federal patent initiatives could cause ‘headwinds’ for drugmakers and their broad filings
Pharmalot Ed Silverman STAT Plus: ViiV will make it easier for generic companies to copy its HIV prevention shot, but it’s not clear when
Pharmalot Ed Silverman STAT Plus: A battle is brewing between a senator and a nonprofit over pharma patenting practices
Pharmalot Ed Silverman STAT Plus: Oxfam wants the SEC to investigate Moderna for ‘misleading’ investors about its Covid patent dispute with NIH
First Opinion Tahir Amin and Priti Krishtel Solving the U.S. drug pricing crisis starts with a crucial confirmation hearing
Opinions+ Andrei Iancu and David Kappos STAT Plus: Why does the FDA want to stop improving medicines via patent ‘areas of concern’?
Pharmalot Ed Silverman STAT Plus: Dutch group sues AbbVie for human rights violations stemming from Humira pricing
Pharmalot Ed Silverman STAT Plus: U.S. delays backing for patent waivers on Covid-19 therapies and diagnostics
Pharmalot Ed Silverman STAT Plus: European Commission says preliminary findings indicate Teva violated antitrust rules
Pharmalot Ed Silverman STAT Plus: Alnylam sues Pfizer and Moderna for patent infringement in development of Covid-19 vaccines
Pharmalot Ed Silverman STAT Plus: Moderna will never enforce Covid-19 vaccine patents in poor countries
Pharmalot Ed Silverman STAT Plus: AbbVie asks the U.S. International Trade Commission to investigate Alvotech’s plans for a biosimilar Humira
Pharmalot Ed Silverman STAT Plus: Facing intense criticism, Moderna pauses bitter dispute with the NIH over Covid-19 vaccine patents
Pharmalot Ed Silverman STAT Plus: U.S. lawmakers accuse patent office of weakening challenges and allowing drug prices to rise
Pharmalot Ed Silverman STAT Plus: Advocates urge Biden to name patent office director that could transform drug pricing
Pharmalot Ed Silverman STAT Plus: Moderna vows not to enforce Covid-19 patents, but advocates say IP should be given to WHO
Pharmalot Ed Silverman STAT Plus: Consumer groups and unions urge FTC to block AbbVie and Allergan merger
Pharmalot Ed Silverman STAT Plus: Pharmalittle: Judge appears to back push for opioid settlement; the CRISPR patent fight lives on
First Opinion Othman Laraki Proposed patent legislation would block research, stifle innovation, and harm patients
Pharmalot Ed Silverman STAT Plus: FTC says pay-to-delay cases fell, prompting trade group to argue legislation isn’t needed
Pharmalot Ed Silverman STAT Plus: Baltimore sues a J&J unit over ‘sham’ patent litigation to extend its monopoly on a cancer drug
Pharmalot Ed Silverman STAT Plus: Pharmalittle: Surprise FDA approval may dampen storm over pricey drug; should the U.S. adopt reference pricing?
Pharmalot Ed Silverman STAT Plus: Pharmalittle: NAFTA deal may hinge on patent protections for drugs; House committee goes after Sacklers
Pharmalot Ed Silverman STAT Plus: Pharmalittle: Allergan depression drug fails three trials; Vertex CEO appears before Parliament
Pharmalot Ed Silverman STAT Plus: Bristol-Myers faces growing opposition to its Celgene deal. Here’s what the wags are saying
First Opinion Peter Kolchinsky and Jessica Sagers We need a Public Domain Day to highlight when drugs go off patent
Pharmalot Ed Silverman STAT Plus: AbbVie must fork over Humira documents after judge slams a ‘nonsense’ argument
Pharma Ed Silverman and Matthew Herper STAT Plus: Regeneron CEO: ‘We need a carrot-and-stick system’ to balance pricing and innovation
Pharmalot Ed Silverman STAT Plus: Pharmalittle: Drug makers to raise prices in January; Novartis names a new oncology chief, again
Pharmalot Ed Silverman STAT Plus: Trump administration report would preclude reclaiming patents as a way to lower drug prices